Welcome to our dedicated page for Koru Med Sys SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KORU Medical Systems’ infusion devices keep chronic-care patients safe, but their SEC disclosures can be just as intricate as the engineering behind a FREEDOM60 pump. Whether you need to trace immunoglobulin device revenue, check a sudden 8-K about a product recall, or monitor KORU Medical Systems insider trading Form 4 transactions, this page is your starting point.
Our platform delivers every KRMD filing the moment it hits EDGAR, then uses AI to translate legal and accounting language into plain English. Stop scrolling through footnotes—AI-powered summaries highlight flow-rate tubing sales in the KORU Medical Systems annual report 10-K simplified, flag shifts in R&D spend in each KORU Medical Systems quarterly earnings report 10-Q filing, and decode board pay in the proxy statement executive compensation. Real-time alerts for KORU Medical Systems Form 4 insider transactions show you exactly when executives buy or sell stock.
Not sure where your answer lives? Follow the investor journey below and click straight into the right document:
- Need today’s sales outlook? Open the latest 8-K material events explained.
- Comparing quarter-over-quarter device margins? Read the 10-Q filing analysis with AI graphs.
- Tracking leadership incentives? Consult the proxy for stock option details.
- Watching executive stock moves? Get KORU Medical Systems Form 4 insider transactions real-time.
From earnings call schedules to understanding KORU Medical Systems SEC documents with AI, every disclosure is organized, summarized and ready for actionable review—no medical-device jargon required.
KORU Medical Systems insider award summary: Christopher Pazdan, the company’s Chief Operating Officer, received equity awards under the 2024 Omnibus Equity Incentive Plan as part of the 2025 Long-Term Incentive Program on 05/12/2025. The awards include two restricted stock unit grants of 21,308 RSUs each (total 42,616 RSUs); one grant vests time-based one-fourth on 05/12/2026 and annually thereafter, the other vests based on performance measured as of 12/31/2027 with potential payout from 0% to 150% of target and specified multipliers, and both convert to one share per vested unit. Pazdan also received an option for 36,077 shares with a $3.21 exercise price that vests one-fourth on 05/12/2026 and annually thereafter and expires on 05/12/2035. The filing states these awards were granted pursuant to the Company’s equity plan.
Thomas Edward Adams, Chief Financial Officer of KORU Medical Systems (KRMD), received equity awards under the company’s 2024 Omnibus Equity Incentive Plan as part of the 2025 Long-Term Incentive Program. The grants include 32,773 restricted stock units that vest one-fourth on May 12, 2026 and annually thereafter, 32,773 performance-based restricted stock units payable at target (the Reporting Person could earn 0%-150% of the reported amount, further multiplied by between 0.5 to 1.5) based on performance as of December 31, 2027 and vesting at 100% on a change in control prior to that date, and an option to purchase 55,583 shares with a stated exercise price of $3.21 that vests one-fourth on May 12, 2026 and annually thereafter. Each reported position is listed as direct ownership.
KORU Medical Systems insider award summary: Adam R. Kalbermatten, the company’s Chief Commercial Officer, received a 300,000-share restricted stock award as an employment inducement and an option to buy 600,000 shares. The restricted shares vest 25% annually beginning July 28, 2026, subject to acceleration under his employment agreement. The option carries a $3.44 exercise price, a listed expiration of August 1, 2035, and a vesting schedule of one-fourth on August 1, 2026 and on each anniversary thereafter for three years.
What this means: The grants align compensation with future service and performance but create potential dilution of up to 900,000 shares if fully issued and exercised. Both holdings are reported as directly owned by the reporting person.
FAQ
What is the current stock price of Koru Med Sys (KRMD)?
What is the market cap of Koru Med Sys (KRMD)?
